Cart
sales@molnova.com
Home - Products - Others - Other Targets - Concizumab

Concizumab

CAS No. 1312299-39-0

Concizumab( —— )

Catalog No. M36873 CAS No. 1312299-39-0

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 439 Get Quote
5MG 717 Get Quote
10MG 1131 Get Quote
25MG 1638 Get Quote
50MG 2236 Get Quote
100MG 2943 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Concizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.
  • Description
    Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia.
  • In Vitro
    ——
  • In Vivo
    Animal Model:Cynomolgus monkeys (target mediated drug disposition (TMDD) model).Dosage:20mg/kg or 200 mg/kg Administration:Intravenous injection/subcutaneous injection Result:Showed a high bioavailability (93%) and the absorption half-life is estimated to be 72 h.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1312299-39-0
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kjalke M, et al. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. 2021 Jul;19(7):1687-1696. ?
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products
Sign In Join Free